UK markets closed

CytRx Corporation (CYTR)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.5860+0.0210 (+3.72%)
At close: 3:59PM EDT

CytRx Corporation

11726 San Vicente Boulevard
Suite 650
Los Angeles, CA 90049
United States
310 826 5648
http://www.cytrx.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees4

Key executives

NameTitlePayExercisedYear born
Mr. Steven A. KriegsmanChairman & CEO1.05MN/A1942
Mr. John Y. CalozCFO & Treasurer500kN/A1952
Dr. Felix Kratz Ph.D.Sr. VP, Drug Devel.N/AN/A1963
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CytRx Corporation, a biopharmaceutical company, engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides albumin companion diagnostic for cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

Corporate governance

CytRx Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.